IDH1 and glioblastoma: Briefly, the study cohort consisted of 28 cases (6.9%) with diffuse astrocytoma IDH-mutant (WHO °II), 38 cases (9.3%) with anaplastic astrocytoma IDH-mutant (WHO °III), 3 cases (0.7%) with anaplastic astrocytoma IDH-wildtype (WHO °III), 33 cases (8.1%) with oligodendroglioma IDH-mutant and 1p/19q codeleted, 11 cases (2.7%) with anaplastic oligodendroglioma IDH-mutant and 1p/19q codeleted, 5 cases (1.2%) with glioblastoma IDH-mutant, 282 cases (69.1%) with glioblastoma IDH-wildtype, and 8 cases (2%) with diffuse midline glioma H3-K27M-mutant.